Bcm-95 Curcumin — Why Bioavailability Is Everything
Quick Read Standard curcumin supplements are poorly absorbed by your body because curcumin doesn’t dissolve well in water and is
We write a new article on supplements every day , all detailed, with citations.
Once a week we send an email containing a list of the last 7 days articles. Please sign up and also feel free to share the articles with friends and family who you think might benefit.
Simon Parrott – Vitacuity Ltd
Vinpocetine is a supplement derived from the periwinkle plant that has been used clinically in Europe and Asia for over 60 years. It works by blocking an enzyme that normally restricts important signalling molecules in brain cells, potentially improving blood flow to the brain and protecting neurons from damage caused by reduced oxygen and inflammation.
Human studies show promising results, particularly in people with existing brain blood flow problems or mild cognitive impairment. A small 2005 trial found vinpocetine improved blood vessel response in stroke patients, while an 18-month study showed significant cognitive improvements in people with mild cognitive impairment. However, these studies were limited in size and the best evidence comes from laboratory research rather than large trials in healthy people.
The strongest case for vinpocetine exists for people with diagnosed cerebrovascular issues. For healthy adults interested in brain health, the biological reasoning is sound and safety appears good, but definitive proof of benefit is still needed. Typical studied doses are around 18mg daily, though you should avoid vinpocetine if taking blood-thinning medications.
Verdict: Vinpocetine has solid mechanistic reasoning and promising early human evidence for brain blood flow and cognitive function, particularly in those with existing cerebrovascular disease, but larger and better-controlled trials are needed to confirm benefits in healthy people.
What if one of the most quietly researched brain supplements in the world has been sitting in plain sight for over sixty years, used clinically across Europe and Asia, yet barely known in mainstream UK wellness circles? Vinpocetine won’t win any influencer awards. It doesn’t have a catchy origin story or a trendy superfood label. It’s a semi-synthetic compound derived from the periwinkle plant, and it has been studied, seriously studied, since the 1960s. The question isn’t whether researchers find it interesting. They clearly do [4]. The question is what the evidence actually shows, and whether that evidence is strong enough to matter to someone who wants to protect their brain as they age. Let’s find out.
To understand vinpocetine, you need to understand one enzyme: phosphodiesterase type 1, or PDE1. Think of PDE1 as a brake pedal on two important signalling molecules inside your brain cells, cAMP (cyclic adenosine monophosphate) and cGMP (cyclic guanosine monophosphate). These two molecules are your brain’s internal messengers. When they’re active, they help neurons communicate, reduce inflammation, and support healthy blood vessel tone. When PDE1 is overactive, it breaks them down too fast, and those benefits are lost [4][12].
Vinpocetine’s primary mechanism is selectively inhibiting PDE1, taking its foot off that brake pedal. When PDE1 is blocked, cAMP and cGMP levels rise. Higher cAMP is associated with antioxidant effects, while higher cGMP is linked to anti-inflammatory activity [1]. In practical terms for your brain, this creates conditions that support better blood vessel function, reduced neuroinflammation, and improved circulation to brain tissue.
But vinpocetine doesn’t stop there. Research has identified at least two other mechanisms: it blocks voltage-gated sodium channels (specifically NaV1.8), which helps limit the cascade of neuronal damage that follows restricted blood flow [4]; and it reduces the influx of calcium into neurons, calcium overload being one of the key drivers of cell death after a stroke or during periods of low oxygen [12].
The result is a compound with what researchers describe as “multifaceted neuroprotective actions” [4], multiple mechanisms working, potentially in an additive or even synergistic way. Synthesised over 60 years ago and marketed under the brand name Cavinton®, vinpocetine has been used clinically for more than five decades [4]. In Eastern Europe, it is prescribed as a medicine. In the UK and US, it is sold as a dietary supplement.
Evidence grade: Promising, small human RCT with measurable haemodynamic outcomes
The most directly relevant human trial for anyone interested in brain blood flow is a double-blind, randomised, placebo-controlled study published in 2005 [10]. Twenty-six patients aged 50–83 with multiple cerebral infarctions (areas of brain damage caused by blocked blood supply) were divided into two groups: 14 received vinpocetine and 12 received placebo. Researchers used functional transcranial Doppler, a technique that measures blood flow velocity in the brain’s blood vessels in real time, alongside neuropsychological testing.
The findings were notable. In acute testing using a breath-holding task (a standard way of measuring how blood vessels respond to changing CO₂ levels), flow velocities were significantly lower in the vinpocetine group immediately after breath holding. This counter-intuitive finding actually reflects improved vascular reactivity, the vessels were responding more efficiently. Over the three-month study period, the vinpocetine group also held steady on one cognitive test (digit span backward) while the placebo group showed measurable decline.
The honest caveat? Twenty-six patients is a small sample. And the researchers themselves noted that “longer lasting and higher dosage of vinpocetine therapy is suggested to prove its potential effect” [10]. This is promising, genuinely promising, but it is not a definitive proof of effect in healthy adults. These were patients with existing brain damage, and the study ran for just three months.
Evidence grade: Promising, open-label study over 18 months with validated cognitive measures
A Hungarian study published in 2012 investigated vinpocetine in patients diagnosed with mild cognitive impairment (MCI), the stage between normal age-related forgetfulness and diagnosable dementia [7]. The treatment arm received oral vinpocetine for 18 months, and patients were assessed at six time points using validated tools including the MMSE (Mini-Mental State Examination), ADAS-Cog (Alzheimer’s Disease Assessment Scale-Cognitive), ADL (Activities of Daily Living), and the Hamilton Depression Scale.
The results were encouraging. Statistically significant improvements were detected in cognitive test scores over the 18-month treatment period. Overall disease status improved, as rated by both patients themselves and independent clinicians using the CGIC-PGIC scale. Daily functioning improved, and mood lifted alongside cognitive gains. Vinpocetine was well-tolerated with no significant safety concerns [7].
This matters because the target population, people with chronic cerebral hypoperfusion (chronically reduced blood flow to the brain) leading to mild cognitive impairment, is exactly the population for whom vinpocetine’s blood-flow enhancing mechanism is most relevant. When the brain isn’t getting enough blood, neurons struggle to function. Vinpocetine’s ability to dilate cerebral blood vessels and reduce vascular resistance may explain why it helped in this group.
The limitation to name clearly: this was not a placebo-controlled trial. Without a control group, we cannot rule out that some improvement came from the natural variability of MCI over time, or from the attention of being in a study. The findings are suggestive and clinically meaningful, but they need replication in a properly controlled format.
Evidence grade: Early stage to Promising, strong mechanistic evidence from lab and animal studies, human data more limited
A major review published in 2026 in the journal *Biomolecules* [4] summarised decades of experimental research on vinpocetine’s neuroprotective mechanisms in cerebral ischaemia, the condition where blood flow to part of the brain is dangerously reduced. The review drew on a large body of in vitro (cell culture) and animal studies to map out exactly what vinpocetine does at the molecular level.
The key mechanisms identified were: PDE1 inhibition (raising cAMP and cGMP signalling), NaV1.8 channel blockade (reducing abnormal sodium influx that damages cells), reduction of oxidative stress, and suppression of the neuroinflammatory cascade triggered when brain tissue is deprived of blood and oxygen [4]. The reviewers noted that these actions are likely “additive or synergistic” under real-world conditions, meaning the mechanisms reinforce each other rather than operating in isolation.
A complementary 2020 critical review [12] focused specifically on stroke and post-stroke outcomes, noting that vinpocetine’s anti-inflammatory, antioxidant, and anti-apoptotic (cell-death-preventing) effects operate both directly through the cAMP/cGMP pathway and indirectly through downstream inflammatory mediators. The same review highlighted that vinpocetine has shown effectiveness as an adjuvant therapy in epilepsy management, reducing seizure frequency by 50% in animal models at 2 mg/kg/day doses, and that it modulates brain monoamine pathways including dopamine and serotonin [12].
A separate 2023 review extended the mechanistic argument to Parkinson’s disease [1][15], suggesting that vinpocetine’s ability to protect dopaminergic neurons (the specific neurons lost in Parkinson’s) via reduced oxidative stress, lipid peroxidation, and calcium overload makes it a plausible candidate for investigation in neurodegenerative disease management. This is early-stage thinking, the human trial evidence in Parkinson’s is minimal, but the mechanistic logic is coherent.
The important honesty point here: the weight of evidence for these mechanisms comes from preclinical research. Lab and animal studies don’t always translate into human benefits at the same effect sizes. This is why the mechanistic story, however compelling, needs more robust human trials behind it.
Evidence grade: Early stage / pharmacological research, relevant to dosing
A 2023 paper in *Pharmaceutics* [3] tackled one of the practical challenges of vinpocetine supplementation: its behaviour in the body. Vinpocetine is metabolised primarily into a compound called apovincaminic acid (AVA), which is its main active metabolite. The paper proposed a population pharmacokinetic model for AVA, based on studies in healthy volunteers comparing three different formulations of vinpocetine.
Why does this matter? Because vinpocetine has relatively low bioavailability when taken orally, meaning a significant portion is broken down before it reaches the bloodstream, and this varies between individuals and formulations. The hepatic first-pass effect (where the liver metabolises a large portion of an orally taken substance before it enters general circulation) is a known limitation [5]. This is why researchers are actively working on vinpocetine derivatives with improved bioavailability [5], and why the form and dosage of any vinpocetine supplement matters in practice.
The clinical implication: not all vinpocetine products are equal. Formulation matters. The doses used in the human studies cited here ranged from standard oral tablet formats, and the 18-month cognitive study used 18mg daily across the treatment period [7]. Understanding how the body processes vinpocetine is an active area of research that may eventually inform much more precise supplement recommendations.
Let’s be completely straight with you here, because this is where the vinpocetine story gets genuinely complicated.
The mechanistic evidence, how vinpocetine works at the molecular level, is substantial and well-characterised after decades of research [4][12]. The preclinical evidence from animal and cell studies is extensive. What we don’t yet have is a large, well-powered, double-blind, placebo-controlled randomised trial in healthy adults that definitively shows vinpocetine improves brain blood flow and cognitive performance over the long term.
The human studies that exist [7][10] are promising but small. The 2005 RCT had just 26 patients and ran for three months [10]. The 18-month cognitive study lacked a placebo control group [7]. These aren’t fatal flaws, they’re normal limitations of early-stage human research, but they mean we cannot claim this is settled science. We’re in the territory of “the evidence is pointing in a consistent direction, but more and better trials are needed.”
There are also questions about dosing. Most clinical studies have used doses in the range of 5–30mg daily, but optimal dosing for cognitive benefits in healthy adults versus those with existing cerebrovascular disease hasn’t been established. The bioavailability problem [3][5] means that the dose on the label may not correspond neatly to what reaches the brain.
Safety appears good. No serious adverse effects have been reported in the studies reviewed here, and multiple sources describe vinpocetine as well-tolerated [7][9]. However, vinpocetine does have mild blood-thinning properties (it reduces platelet aggregation) which could be a consideration for anyone on anticoagulant medications. One regulatory note worth flagging: the US FDA raised concerns in 2020 about whether vinpocetine is legally classifiable as a dietary supplement, though this is a regulatory question rather than a safety question per se.
Finally, almost all of the research on cerebrovascular effects has been conducted in patients with existing conditions, stroke, multi-infarct disease, mild cognitive impairment, chronic hypoperfusion. The question of whether vinpocetine provides meaningful benefit to a cognitively healthy 50-year-old with normal circulation is genuinely unanswered. The mechanism suggests it could help; the evidence doesn’t yet confirm it does.
Here’s how a sensible, well-informed person should think about vinpocetine in 2024.
This is not a speculative supplement based on trend or folklore. It has sixty-plus years of clinical use in Europe, a well-understood mechanism of action, preclinical evidence that is genuinely robust, and human data that, while limited in scale, consistently points in the right direction [4][7][10][12]. The profile of mechanisms is particularly interesting: it doesn’t just dilate blood vessels, it also reduces oxidative stress, damps neuroinflammation, and protects neurons from calcium overload [1][4]. That’s a meaningful combination for anyone concerned about brain health over the long term.
The evidence is strongest for people with existing cerebrovascular issues, reduced brain blood flow, early cognitive impairment, stroke recovery. If that describes you or someone close to you, the case for vinpocetine is meaningfully stronger than for a healthy 45-year-old with no symptoms.
For the cognitively healthy person in midlife who wants to think proactively about brain ageing, the evidence is promising rather than definitive. The biological rationale is sound. The safety profile is good at normal doses. The risk of trying it is low; the potential benefit aligns with what we care most about (circulation, neuroprotection, and long-term cognitive resilience).
Doses in the human research ranged broadly, but studies showing cognitive benefit used around 18mg daily [7]. If you choose to try vinpocetine, stick within studied ranges and avoid it if you are taking blood-thinning medications without speaking to your GP first. As with any supplement, it works best as part of a broader approach, good sleep, regular movement, cardiovascular fitness, and a diet that supports brain health all influence cerebral blood flow too.
Vitacuity reviewed over 1.77 million research papers to identify and select the most relevant evidence on this topic. Vinpocetine earned its place in that selection honestly: not because it’s fashionable, but because the science, imperfect as it still is, makes it one of the more coherent and consistently researched compounds in the brain health space. That’s worth knowing.
[1] New insights on the potential effect of vinpocetine in Parkinson’s disease: one of the neglected warden and baffling topics. (2023). DOI: 10.1007/s11011-023-01254-y | https://pubmed.ncbi.nlm.nih.gov/37335452/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348926/
[3] Clinical Pharmacology of Vinpocetine: Properties Revisited and Introduction of a Population Pharmacokinetic Model for Its Metabolite, Apovincaminic Acid (AVA). (2023). DOI: 10.3390/pharmaceutics15102502 | https://pubmed.ncbi.nlm.nih.gov/37896263/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610279/
[4] Vinpocetine-An “Old” Drug with a New Face: Moving Toward a Better Understanding of Its Neuroprotective Mechanism of Action. (2026). DOI: 10.3390/biom16030454 | https://pubmed.ncbi.nlm.nih.gov/41897389/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13023651/
[5] Synthesis and pharmacological activity of vinpocetine derivatives. (2024). https://pubmed.ncbi.nlm.nih.gov/38454939/
[7] Study of the effects of vinpocetin on cognitive functions. (2012). https://pubmed.ncbi.nlm.nih.gov/23136730/
[9] Role of vinpocetine in cerebrovascular diseases. (2011). DOI: 10.1016/s1734-1140(11)70574-6 | https://pubmed.ncbi.nlm.nih.gov/21857073/
[10] Acute and chronic effects of vinpocetine on cerebral hemodynamics and neuropsychological performance in multi-infarct patients. (2005). DOI: 10.1177/0091270005279363 | https://pubmed.ncbi.nlm.nih.gov/16100299/
[12] Role of vinpocetine in ischemic stroke and poststroke outcomes: A critical review. (2020). DOI: 10.4103/bc.bc_46_19 | https://pubmed.ncbi.nlm.nih.gov/32166194/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045535/
[15] New insights on the potential effect of vinpocetine in Parkinson’s disease: one of the neglected warden and baffling topics. (2023). DOI: 10.1007/s11011-023-01254-y | https://pubmed.ncbi.nlm.nih.gov/37335452/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348926/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Standard curcumin supplements are poorly absorbed by your body because curcumin doesn’t dissolve well in water and is
Quick Read Your gut bacteria and brain communicate through a direct pathway. When you eat prebiotic fibre, your gut bacteria
The nutrients that matter, the forms that work, and the claims to ignore.
